Organon Teknika signs distribution deal with Toyobo:
This article was originally published in Clinica
Organon Teknika has signed a sub-licensing agreement with Toyobo, granting the Japanese company non-exclusive rights to market Cangene's NASBA technology. The deal will cover infectious disease screening, and cancer and genetic testing in Japan. Cangene was recently granted a US patent for NASBA, covering RNA amplification and a European patent in June 1994 (see Clinica No 609, p 16). Organon is a partner of Cangene (Canada) and a subsidiary of Dutch company Akzo Nobel.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.